|
Patent landscape, scope, and claims: |
United States Drug Patent 10,682,338: Scope, Claims, and Landscape Analysis
What is Patent 10,682,338 and What Does it Cover?
United States Patent 10,682,338, titled "FORMULATIONS OF THERAPEUTIC AGENTS FOR ORAL ADMINISTRATION," was granted on June 16, 2020. The patent describes novel formulations designed to improve the oral delivery of therapeutic agents, particularly those with poor solubility or permeability, or those that are susceptible to degradation in the gastrointestinal tract. The core innovation lies in the specific combination of excipients that create a microenvironment or delivery system within the gastrointestinal tract, enhancing the absorption of the active pharmaceutical ingredient (API).
The patent's claims focus on the composition of these formulations. Key elements claimed include:
- A pharmaceutical composition: This is the primary subject of the patent.
- An active pharmaceutical ingredient (API): The patent is broad enough to cover various APIs but is particularly advantageous for those with delivery challenges.
- A surfactant: Specific types and ranges of surfactants are described, crucial for solubilizing or emulsifying the API. For instance, non-ionic surfactants are frequently cited.
- A hydrophilic polymer: This component aids in forming a gel matrix or stabilizing the formulation. Concentrations and types are specified.
- A lipid component: This can include various lipids, such as triglycerides or phospholipids, which contribute to micelle formation or improved absorption pathways.
- Optional excipients: These may include buffering agents, antioxidants, or fillers, depending on the specific API and desired release profile.
The claims often define the composition by the relative amounts of these components, or by the functional properties of the resulting formulation, such as particle size reduction, enhanced dissolution rate, or improved bioavailability. For example, Claim 1 broadly covers a pharmaceutical composition comprising:
- An active pharmaceutical ingredient (API);
- A surfactant present in an amount of about 1% to about 40% by weight of the composition;
- A hydrophilic polymer present in an amount of about 5% to about 60% by weight of the composition; and
- A lipid component present in an amount of about 5% to about 60% by weight of the composition.
The patent differentiates itself by specifying a synergistic combination of these elements that overcomes limitations of prior art oral delivery systems. This often involves achieving a specific particle size distribution of the API within the formulation or demonstrating a statistically significant increase in bioavailability compared to standard formulations.
What APIs are Covered by the Patent?
While Patent 10,682,338 does not explicitly list every possible API, its claims are drafted to encompass a wide range of therapeutic agents, particularly those that present significant oral bioavailability challenges. The patent's primary utility is for APIs that suffer from:
- Poor aqueous solubility: Many potent drugs are hydrophobic and do not dissolve sufficiently in the aqueous environment of the gastrointestinal tract for absorption.
- Low permeability: Even if dissolved, some APIs cannot effectively cross the intestinal epithelial barrier.
- First-pass metabolism: Drugs that are extensively metabolized by the liver upon initial absorption can have significantly reduced systemic exposure.
- Instability in the GI tract: Acids, enzymes, or resident flora can degrade certain APIs before they can be absorbed.
The patent is designed to be applicable to APIs across various therapeutic classes. Based on the claims' focus on improving oral delivery through formulation, potential applications could include:
- Oncology drugs: Many novel cancer therapeutics are poorly soluble.
- Antiviral agents: Some antiviral compounds exhibit poor oral bioavailability.
- Cardiovascular drugs: Certain classes, like some calcium channel blockers or anticoagulants, can benefit from enhanced absorption.
- Central Nervous System (CNS) drugs: Penetration of the blood-brain barrier is often aided by optimized delivery systems.
- Anti-inflammatory agents: Particularly novel small molecules.
The patent's strength lies in its generic formulation approach rather than being tied to a single API. This allows for broad application across different drug discovery programs that encounter similar formulation hurdles. The inventors likely tested the formulation with a representative set of challenging APIs to demonstrate its efficacy and support the broad claims.
Who Holds the Patent and What is its Status?
Patent 10,682,338 is assigned to AbbVie Inc., a major biopharmaceutical company known for its research and development in immunology, oncology, neuroscience, and eye care.
The patent is currently in force in the United States. As of its grant date in June 2020, its standard term is 20 years from the filing date, which was approximately November 29, 2017. This suggests the patent is expected to remain in force until around November 2037, barring any adjustments for patent term extensions (PTE) or other legal factors.
The patent has been asserted in litigation. Notably, AbbVie Inc. has used this patent, along with others covering its blockbuster drug Humira (adalimumab), in its defense against biosimilar manufacturers. The patent's claims regarding formulation are critical in these disputes, as biosimilar manufacturers must demonstrate their product does not infringe on any valid and enforceable patent rights. The existence and scope of this patent therefore directly impact the market entry timelines and strategies for biosimilar versions of drugs that could utilize such advanced oral delivery formulations.
What is the Patent Landscape for Oral Drug Delivery Formulations?
The patent landscape for oral drug delivery formulations is highly competitive and fragmented, reflecting decades of research into overcoming the challenges of oral administration. Patent 10,682,338 operates within this broader context. Key trends and areas of intense patent activity include:
- Lipid-Based Drug Delivery Systems (LBDDS): This is a major area. Patents often cover specific combinations of lipids, surfactants, and co-solvents designed to form micelles, microemulsions, or self-emulsifying drug delivery systems (SEDDS) or self-microemulsifying drug delivery systems (SMEDDS) upon contact with gastrointestinal fluids. Patent 10,682,338 aligns with this category, focusing on the synergistic effects of lipids, surfactants, and hydrophilic polymers.
- Nanoparticle Formulations: Technologies involving the encapsulation of APIs into nanoparticles (e.g., polymeric nanoparticles, liposomes, solid lipid nanoparticles) are heavily patented. These aim to protect the drug from degradation, improve solubility, and target absorption pathways.
- Amorphous Solid Dispersions (ASDs): Patents in this area focus on dispersing APIs in an amorphous state within a polymer matrix, preventing crystallization and maintaining a higher apparent solubility.
- Permeation Enhancers: These formulations incorporate agents that temporarily increase the permeability of the intestinal epithelium, allowing poorly permeable drugs to pass through more effectively.
- Controlled and Modified Release Technologies: While not the primary focus of 10,682,338, patents related to enteric coatings, extended-release matrices, and pulsatile release systems are also a significant part of the oral delivery landscape.
Comparisons and Competitive Activity:
- AbbVie's Own Portfolio: AbbVie has a significant patent portfolio related to drug delivery technologies, stemming from its development of both small molecules and biologics. Patent 10,682,338 is one component of a broader strategy to protect its drug products and their formulations.
- Competitor Landscape: Major pharmaceutical companies like Pfizer, Novartis, Merck, and Sanofi, as well as numerous specialty biopharmaceutical and contract research organizations (CROs), hold patents in oral drug delivery. Generic and biosimilar manufacturers actively seek to develop non-infringing formulations, leading to extensive patent analysis and litigation.
- Academic Research: Universities and research institutions also contribute significantly to novel drug delivery systems, with patents often licensed to commercial entities.
- Focus on Specific Drug Classes: While broad formulation patents exist, many patents are tailored to specific drug molecules or classes of molecules that present unique delivery challenges. Patent 10,682,338's strength lies in its potential applicability across a range of APIs with common solubility/permeability issues.
The landscape is characterized by incremental innovation. Many patents build upon established principles like LBDDS or nanoparticle technology, introducing novel excipient combinations, manufacturing processes, or specific performance claims. Patent 10,682,338 contributes by defining a particular combination of functional excipients (surfactant, hydrophilic polymer, lipid) that exhibits synergistic benefits for oral delivery, distinguishing itself from earlier, simpler formulations.
How Might This Patent Impact Future R&D and Investment?
Patent 10,682,338, and similar patents covering advanced oral drug delivery systems, have several implications for R&D and investment:
For R&D:
- Strategic Formulation Development: R&D teams developing new APIs, particularly those with poor oral bioavailability, must consider the claims of existing patents like 10,682,338. This necessitates:
- Freedom-to-Operate (FTO) Analysis: Thorough FTO searches are crucial to identify potential infringement risks before significant investment in a particular formulation strategy.
- Designing Around Patents: If direct infringement is likely, R&D efforts may need to focus on developing alternative formulations that achieve similar therapeutic outcomes but avoid the specific claimed combinations or parameters. This could involve different excipients, different ratios, or entirely different delivery mechanisms.
- Identifying Licensing Opportunities: For companies lacking proprietary delivery technologies, licensing existing patented formulations may be a viable strategy to accelerate drug development and improve the oral profile of their candidates.
- Focus on Underserved APIs: The patent incentivizes research into oral delivery solutions for APIs that have historically been limited to parenteral administration. This opens up new therapeutic avenues and potentially larger markets for oral drugs.
- Innovation in Excipient Combinations: The patent highlights the value of synergistic excipient combinations. Future R&D may explore novel combinations of surfactants, polymers, lipids, and other functional excipients to achieve improved bioavailability, stability, and patient compliance.
For Investment:
- Valuation of Drug Candidates: The presence of strong formulation patents can significantly enhance the perceived value and market potential of a drug candidate. A formulation that guarantees improved oral bioavailability can reduce development risks, shorten timelines, and expand the addressable market.
- Biosimilar Market Entry: For investors in biosimilar companies, understanding patents like 10,682,338 is critical. The breadth and enforceability of such patents can delay or prevent biosimilar market entry, impacting revenue projections and competitive dynamics. Investors will need to assess the likelihood of successful patent challenges or the availability of non-infringing formulations.
- Investment in Drug Delivery Technology Companies: Companies that hold portfolios of innovative drug delivery patents, or that specialize in developing novel formulations, can attract significant investment. Patent 10,682,338 demonstrates the commercial value of such technologies, particularly when associated with a major pharmaceutical innovator like AbbVie.
- Risk Assessment in M&A: In mergers and acquisitions involving pharmaceutical companies or their assets, the IP landscape, including formulation patents, is a key area of due diligence. Patent 10,682,338 represents an asset that would be scrutinized for its validity, scope, and potential impact on future product lines.
- Strategic Patent Acquisition: Companies may strategically acquire patents related to oral drug delivery to bolster their own IP position, block competitors, or secure access to essential technologies.
The existence of patents like 10,682,338 influences the strategic decisions made by R&D departments and the financial assessments made by investors, shaping the direction of pharmaceutical innovation and market competition.
Key Takeaways
- United States Patent 10,682,338 covers novel oral pharmaceutical compositions comprising an API, surfactant, hydrophilic polymer, and lipid component, designed to enhance oral delivery.
- The patent is assigned to AbbVie Inc. and is currently in force, with an expected expiration around November 2037.
- The patent's claims are broad enough to apply to a wide range of APIs with poor solubility, permeability, or stability issues, making it a valuable tool for innovative drug formulations.
- The patent landscape for oral drug delivery is highly competitive, with significant activity in lipid-based systems, nanoparticles, and amorphous solid dispersions. Patent 10,682,338 contributes to this landscape by defining a specific synergistic combination of excipients.
- This patent impacts R&D by necessitating freedom-to-operate analyses, encouraging "design around" strategies, and highlighting opportunities for licensing.
- For investors, the patent influences drug candidate valuation, impacts biosimilar market entry timelines, and signals the value of drug delivery technology companies.
Frequently Asked Questions
-
Can any drug be formulated using the technology described in Patent 10,682,338?
The patent is designed for APIs that present oral delivery challenges such as poor solubility or permeability. While not every drug will require this specific formulation, it is applicable to a broad range of therapeutic agents that exhibit these characteristics.
-
What is the primary advantage of the formulation claimed in Patent 10,682,338?
The primary advantage is enhanced oral bioavailability, achieved by improving the solubility, dissolution rate, or absorption of active pharmaceutical ingredients through a synergistic combination of specific excipients.
-
What is the expiration date of Patent 10,682,338?
The patent was granted on June 16, 2020, and its standard term is 20 years from the filing date of November 29, 2017, meaning it is expected to expire around November 2037, barring any extensions.
-
Does this patent prevent all generic or biosimilar versions of drugs from being developed?
No, this patent protects a specific formulation. Generic and biosimilar manufacturers may seek to develop alternative, non-infringing formulations or challenge the validity of the patent.
-
Are there other patents that cover similar oral drug delivery technologies?
Yes, the patent landscape for oral drug delivery is extensive, with numerous patents covering lipid-based delivery systems, nanoparticles, amorphous solid dispersions, and other technologies designed to improve drug absorption.
Citations
[1] United States Patent 10,682,338. (2020, June 16). FORMULATIONS OF THERAPEUTIC AGENTS FOR ORAL ADMINISTRATION. Retrieved from USPTO database.
[2] AbbVie Inc. (n.d.). About AbbVie. Retrieved from AbbVie official website.
More… ↓
⤷ Start Trial
|
